There is an increasing demand worldwide to appropriately judge the effects of various interventions in medicine, social welfare, elderly care and education, as well as to increase individuals’ Quality of Life (QOL) and create a health society.
Evaluations to fulfill these needs cannot be solely based on objective or physical measures; rather, it involves subjective reports of people receiving the intervention that serve as important points of reference.
The development of methods to accurately measure and understand QOL and other patient-reported outcomes (PROs) as well as the promotion of scientific research employing those methods are required.
Japanese Society for QOL-PRO research was established with goals to create an opportunity for a wide range of researchers involved in the studies of QOL-PRO research to exchange information, conduct high-quality studies, and return the benefits of these efforts back to the society as a whole.
|President||Yoshimi Suzukamo, PhD.||Tohoku University, Sendai, Japan.|
|Directors||Mariko Naito, DDS, PhD.||Hiroshima University, Hiroshima, Japan. (Vice President)|
|Shinya Saito, MD. PhD.||Okayama University, Okayama, Japan.|
|Councilors||Rika Hayashida, RN, MS.||University of Nagasaki, Nagasaki, Japan.|
|Makoto Hikosaka, MD.||National Center for Child Health and Development, Tokyo, Japan.|
|Tsuguo Iwatani, MD, PhD.||National Cancer Center Hospital East, Tokyo, Japan.|
|Yuichiro Kikawa, MD.||Kansai Medical University, Osaka, Japan.|
|Tatsunori Murata, PhD.||CRECON Medical Assessment Inc., Tokyo, Japan.|
|Tatsuto Nishigori, MD, PhD.||Kyoto Univesity, Kyoto, Japan.|
|Shinichi Noto, PhD.||Niigata University of Health and Welfare, Niigata, Japan.|
|Kojiro Shimozuma, MD, PhD.||College of Life Sciences, Ritsumeikan University, Kusatsu, Japan. (Former President)|
|Takeru Shiroiwa, PhD.||National Institute of Public Health, Wako, Japan.|
|Naruto Taira, MD, PhD.||Okayama University, Okayama, Japan.|
|Nobuichiro Tamura, MD.||Kurashiki Central Hospital, Kurashiki, Japan.|
|Erika Tanaka.||Bayer Yakuhin Ltd.|
|Special Adviser||Kathleen W. Wyrwich||Pfizer Patient-Centered Outcomes Assessment (PCOA) Center of Excellence|